Neurocrine Biosciences Valuation
| NBIX Stock | USD 111.92 1.85 1.68% |
At this time, the firm appears to be undervalued. Neurocrine Biosciences secures a last-minute Real Value of $124.69 per share. The latest price of the firm is $111.92. Our model forecasts the value of Neurocrine Biosciences from analyzing the firm fundamentals such as Current Valuation of 10.54 B, return on equity of 0.14, and Profit Margin of 0.14 % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Neurocrine Biosciences' valuation include:
Price Book 4.3116 | Enterprise Value | Enterprise Value Ebitda 16.484 | Price Sales 4.7377 | Forward PE 22.5225 |
Undervalued
Today
Please note that Neurocrine Biosciences' price fluctuation is very steady at this time. Calculation of the real value of Neurocrine Biosciences is based on 3 months time horizon. Increasing Neurocrine Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Neurocrine Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Neurocrine Stock. However, Neurocrine Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 111.92 | Real 124.69 | Target 167.67 | Hype 111.77 | Naive 104.35 |
The intrinsic value of Neurocrine Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Neurocrine Biosciences' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Neurocrine Biosciences helps investors to forecast how Neurocrine stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Neurocrine Biosciences more accurately as focusing exclusively on Neurocrine Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Neurocrine Biosciences' intrinsic value based on its ongoing forecasts of Neurocrine Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Neurocrine Biosciences' closest peers.
Neurocrine Biosciences Cash |
|
Neurocrine Valuation Trend
Analysing the historical paterns of Neurocrine Biosciences' enterprise value and its market capitalization is a good way to estimate and gauge the value of Neurocrine Biosciences over time and is usually enough for investors to make rational market timing decisions.
Neurocrine Revenue by Product
Neurocrine Biosciences Total Value Analysis
Neurocrine Biosciences is now forecasted to have valuation of 10.54 B with market capitalization of 11.16 B, debt of 455.1 M, and cash on hands of 799.4 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Neurocrine Biosciences fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
10.54 B | 11.16 B | 455.1 M | 799.4 M |
Neurocrine Biosciences Investor Information
About 98.0% of the company shares are owned by institutional investors. The book value of Neurocrine Biosciences was now reported as 26.05. The company has Price/Earnings To Growth (PEG) ratio of 0.27. Neurocrine Biosciences last dividend was issued on the 29th of December 1995. Based on the key indicators related to Neurocrine Biosciences' liquidity, profitability, solvency, and operating efficiency, Neurocrine Biosciences is doing better financially today then in previous quarter. It has a moderate odds of reporting better financial numbers in April.Neurocrine Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Neurocrine Biosciences has an asset utilization ratio of 63.34 percent. This suggests that the Company is making $0.63 for each dollar of assets. An increasing asset utilization means that Neurocrine Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Neurocrine Biosciences Ownership Allocation
Neurocrine Biosciences maintains a total of 99.7 Million outstanding shares. The majority of Neurocrine Biosciences outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neurocrine Biosciences to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neurocrine Biosciences. Please pay attention to any change in the institutional holdings of Neurocrine Biosciences as this could imply that something significant has changed or is about to change at the company. On December 18, 2024, Representative Michael McCaul of US Congress acquired $15k to $50k worth of Neurocrine Biosciences's common stock.Neurocrine Biosciences Profitability Analysis
The company reported the previous year's revenue of 2.36 B. Net Income was 341.3 M with profit before overhead, payroll, taxes, and interest of 1.59 B.About Neurocrine Biosciences Valuation
Our relative valuation model uses a comparative analysis of Neurocrine Biosciences. We calculate exposure to Neurocrine Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Neurocrine Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 2.3 B | 2.4 B | |
| Pretax Profit Margin | 0.21 | 0.22 | |
| Operating Profit Margin | 0.24 | 0.25 | |
| Net Profit Margin | 0.14 | 0.15 | |
| Gross Profit Margin | 0.99 | 1.03 |
Neurocrine Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 103.7 M | |
| Quarterly Earnings Growth Y O Y | -0.307 | |
| Forward Price Earnings | 22.5225 |
Neurocrine Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Neurocrine Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Neurocrine we look at many different elements of the entity such as Neurocrine's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Neurocrine Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Neurocrine Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Neurocrine Biosciences' worth.Additional Tools for Neurocrine Stock Analysis
When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.